Title: NOVEL USES FOR ANTI-IGE THERAPY

Abstract: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status/ with a therapeutically effective amount of an anti-IgE antibody. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found, in their own right, to be useful if the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammalian irurnuimoglobin E (e.g., human immunglobulin E) such as humanized anti-IgG antibody humanized murine monoclonal antibody, and/or Qmalizumab.
# INTERNATIONAL SEARCH REPORT

**A. CLASSIFICATION OF SUBJECT MATTER**

**IPC:** A61K 39/00(2006.01), 39/395(2006.01); C07K 16/00(2006.01); C12P 21/08(2006.01)

**USPC:** 424/133.1, 139.1, 145.1, 805, 810, 850/387.3, 388.25, 862, 868

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S.: 424/133.1, 139.1, 145.1, 805, 810; 530/387.3, 388.25, 862, 868

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

- **‘A’** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- **‘E’** earlier application or patent published on or after the international filing date
- **‘L’** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- **‘O’** document referring to an oral disclosure, use, exhibition or other means
- **‘P’** document published prior to the international filing date but later than the priority date claimed
- **‘X’** document of particular relevance; the claimed invention cannot be considered new or cannot be considered to involve an inventive step when the document is taken alone
- **‘Y’** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- **‘&’** document member of the same patent family

Date of the actual completion of the international search: 30 April 2008 (30.04.2008)

Name and mailing address of the ISA/US

Mail Stop PCT. Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Date of mailing of the international search report: 15 May 2008

Authorized official: [Signature]

Telephone No. (571) 272-1600

Form PCT/ISA/210 (second sheet) (April 2007)
Continuation of B. FIELDS SEARCHED Item 3:
USPAT USPGUB EPO JPO DERWENT (EAST)
MEDLINE AGRICOLA BIOSIS CAPLUS EMBASE SCISEARCH (STN)
IgE, antibody, immunoglobulin, COPD, e25, omalizumab